IQVIA HoldingsFRA:QTS +1.58%88 Market Cap is €28,079 Mil as of Jun. 29, 2026. GuruFocus rates FRA:QTS with a GF Score™ of 88/100 and a GF Value™ of €217.39 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 218 Medical Diagnostics & Research companies, IQVIA Holdings ranks better than 95.87% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). IQVIA Holdings's share price for the quarter that ended in Mar. 2026 was €146.8. IQVIA Holdings's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 167 Mil. Therefore, IQVIA Holdings's market cap for the quarter that ended in Mar. 2026 was €24,501 Mil.
IQVIA Holdings's quarterly market cap
increased
from Sep. 2025 (€27,452 Mil) to Dec. 2025 (€32,436 Mil) but then
declined
from Dec. 2025 (€32,436 Mil) to Mar. 2026 (€24,501 Mil).
IQVIA Holdings's annual market cap
declined
from Dec. 2023 (€37,752 Mil) to Dec. 2024 (€33,221 Mil) and
declined
from Dec. 2024 (€33,221 Mil) to Dec. 2025 (€32,436 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. IQVIA Holdings's Enterprise Value for Today is €40,479 Mil.
IQVIA Holdings (FRA:QTS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
IQVIA Holdings Market Cap Related Terms
IQVIA Holdings Market Cap Historical Data
* Premium members only.
The historical data trend for IQVIA Holdings's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IQVIA Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
IQVIA Holdings's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings (FRA:QTS) has a Market Cap of €28,079 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on IQVIA Holdings and its competitors. According to the industry distribution chart, IQVIA Holdings ranks #9 out of 218 companies in the Medical Diagnostics & Research industry, placing it in the top 4.1%.
Is IQVIA Holdings' Market Cap too high?
IQVIA Holdings' current Market Cap is €28,079 Mil. Based on the distribution chart, IQVIA Holdings ranks #9 out of 218 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IQVIA Holdings has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' Market Cap compare to WAT and ILMN?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #9 out of 218 companies for Market Cap. This places IQVIA Holdings in the top 4% of its industry — outperforming the majority of peers. The industry median Market Cap is 54.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 54.77, based on 218 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on IQVIA Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 54.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IQVIA Holdings's current Market Cap is €28,079 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (FRA:QTS) is currently considered Modestly Undervalued. The stock's GF Value™ is €217.39, compared to a current price of €166.85 — trading 23.2% below its estimated fair value. The current Market Cap is €28,079 Mil. IQVIA Holdings' overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For IQVIA Holdings (FRA:QTS), the current Market Cap is €28,079 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (FRA:QTS) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued.
The current stock price of €166.85 is trading 23.2% below its estimated GF Value™ of €217.39.
GuruFocus considers IQVIA Holdings to be Modestly Undervalued.
Key valuation signals for FRA:QTS:
Market Cap: €28,079 Mil
GF Value™: €217.39 vs. price of €166.85 (23.2% below fair value)
No single metric tells the full story. See the FRA:QTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
88GF Score
Get the complete analysis for FRA:QTS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:QTS has been successfully added to your 
